Clinical Tumor Anemia Registry (TAR)

The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Hematologic Diseases Hemic and Lymphatic Diseases Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

iOMEDICO

Freiburg im Breisgau, 79108, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologically confirmed malignant disease
Hemoglobin level < 11 g/dl (female) or < 12 g/dl (male)
Start of antianemic therapy no more than 7 days prior to informed consent
Performance status 0 - 3 (Karnofsky-Index >= 40%)
Minimum age: 18 years
Informed written consent

Exclusion criteria

Hypersensitivity against antianemic therapies
Myelodysplastic Syndrome
Experimental antianemic therapy

Treatment and study plan

Primary outcomes

Documentation of therapies

Time frame: 12 weeks per patient

Overview on the current routine treatment of anemia in cancer patients in Germany

Secondary outcomes

Change in hemoglobin levels and QoL

Time frame: 12 weeks per patient

Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP).

Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.

Sponsors and collaborators

Lead sponsor

iOMEDICO AG

Industry

Collaborators

ASORS (Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft)

Registry information

Official study title

Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia

Acronym: TAR

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2016
First posted: Feb 21, 2013
Registry last updated: Feb 29, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed